GALT Chief Medical Officer Khurram Jamil Buys $11K of Stock

Khurram Jamil Adds More Shares of Galectin Therapeutics

Galectin Therapeutics Inc. (NasdaqCM: GALT) insider Khurram Jamil added to his position in the biotechnology firm on June 26, 2026. The company's Chief Medical Officer picked up 4,570 shares at an average price of $2.37 per share. The transaction came out to a total value of $10,813.99, according to regulatory filings with the SEC.

Following Up on Recent Insider Activity

The June 26 transaction continues a busy week of personal stock acquisitions for executive leadership at the company. Just a few days prior on June 23, 2026, Jamil bought 7,557 shares at a price of $1.23 per share, totaling $9,295.11. Another insider, Harold Shlevin, also stepped up on June 26, 2026, by purchasing 7,732 shares at $1.23 per share for a total of $9,510.36. These purchases build on a sequence of insider trades that show management putting personal capital into the clinical-stage enterprise.

Stock Price Movement and Market Levels

Shares of Galectin Therapeutics traded around $4.64 recently. The equity moves within a 52-week range defined by a low of $2.03 and a high of $7.13. Because the company focuses on early-stage drug development and does not generate traditional net income, it currently has no positive P/E ratio to display.

Analysts Set New Price Targets

Wall Street coverage of the firm remains active through individual firm updates. On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on the stock alongside an $11.00 price target. The single analyst opinion currently tracking the company anchors its consensus target at that same $11.00 level.

What the Company Does

Galectin Therapeutics operates as a clinical-stage biopharmaceutical firm based in Norcross, Georgia. The organization works on creating new medical therapies targeting fibrotic diseases and cancer, with lead product candidates directed toward conditions like MASH with advanced fibrosis and cirrhosis. With a small team of employees, the business continues to advance its clinical pipeline through ongoing trials.

Looking Ahead at Corporate Milestones

Market participants will continue watching the company for clinical updates and upcoming financial disclosures. The next corporate earnings release is expected around August 11, 2025. Observers will also track future SEC reports to see how insider ownership evolves through the rest of the year.